Daiichi Sankyo has added a preclinical lung cancer collaboration with Dana-Farber Cancer Institute to its fast-growing list of oncology alliances.

AstraZeneca has halted a Phase IIa trial of the severe asthma drug it licensed from Synairgen, wiping 40% off the latter's share price.

Arrowhead Pharmaceuticals and Spring Bank Pharmaceuticals have partnered to test a couple of hepatitis B candidates in combination.

The candidate just won a breakthrough designation from the FDA and priority medicine status from the EMA in July, with an FDA submission expected next year.

Amgen has become the latest big-name drugmaker to strike a deal to access Nuevolution’s discovery platform.

Boehringer has backed out of the $730 million lung cancer pact it struck with Hanmi Pharmaceutical after reviewing the data and competitive landscape.

Gene therapy player bluebird bio has partnered with German biotech Medigene to develop and commercialize T cell receptor (TCR) immunotherapies against four…

Roche’s Genentech is pairing up with Hanmi Pharmaceutical to gain access to its Phase I pan-RAF inhibitor.

Celgene is paying up under a February 2014 deal with Abide Therapeutics to exercise its option for ex-U.S. rights to its only clinical candidate.